ARTICLE | Clinical News
Perifosine: Phase II data
October 4, 2004 7:00 AM UTC
In a Phase II trial in 23 patients, one patient had a confirmed partial response lasting more than 5 months and 2 remained progression-free at 6 months. KRX-0401 was well tolerated at the doses used. ...